

Can't fill your Darunavir prescription? Learn about alternative HIV medications your doctor may consider, including other protease inhibitors and INSTIs.
Being unable to fill your Darunavir prescription can be stressful — especially when you know how important it is to stay on your HIV treatment without interruption. Whether the issue is pharmacy stock, insurance problems, side effects, or cost, it helps to know that there are other effective HIV medications available.
Important: Never switch medications on your own. Any change to your HIV treatment must be made by your doctor based on your viral load, treatment history, resistance testing, and overall health. This article is for educational purposes — always talk to your prescriber before making changes.
Darunavir (brand name: Prezista) is an HIV protease inhibitor. It works by blocking the HIV protease enzyme, which the virus needs to cut large viral proteins into smaller pieces that form new, infectious HIV particles. Without a functional protease enzyme, HIV can't replicate properly.
Darunavir is always taken with a pharmacokinetic booster — either Ritonavir or Cobicistat — which slows the breakdown of Darunavir in your body, keeping blood levels high enough to fight the virus effectively. It's available as standalone tablets, as part of Prezcobix (Darunavir + Cobicistat), and in the complete single-tablet regimen Symtuza.
For a deeper look at how this drug works, read our article on how Darunavir works: mechanism of action explained.
Below are medications your doctor may consider if Darunavir isn't available or isn't the right fit. These include other protease inhibitors as well as medications from different drug classes.
Atazanavir is another HIV protease inhibitor that works in a similar way to Darunavir. It's also boosted with Ritonavir or Cobicistat and is taken once daily with food.
Atazanavir is often considered for patients who are treatment-naive (have never taken HIV drugs before) and is a reasonable swap for Darunavir in some cases.
Lopinavir/Ritonavir is a combination protease inhibitor that comes pre-formulated with its booster. It was one of the earliest boosted PIs and has a long track record.
This is sometimes used when other protease inhibitors aren't available, especially in resource-limited settings.
Dolutegravir is not a protease inhibitor — it's an integrase strand transfer inhibitor (INSTI). It works by blocking a different enzyme (integrase) that HIV needs to insert its genetic material into your cells.
Dolutegravir is a first-line recommended treatment in current HIV guidelines and is an excellent option for many patients.
Biktarvy is a complete single-tablet HIV regimen that combines an INSTI (Bictegravir) with two NRTIs (Emtricitabine and Tenofovir Alafenamide). One pill, once a day.
Biktarvy is currently the most prescribed HIV medication in the United States and is a preferred first-line option in major treatment guidelines.
Switching HIV medications isn't as simple as picking another drug off the list. Your doctor will consider several factors:
In many cases, your doctor may want to keep you on a protease inhibitor–based regimen (like Atazanavir) if that's what your resistance profile supports. In other cases, switching to an INSTI-based regimen may be the best move.
If you can't fill your Darunavir prescription, there are effective alternatives available — but always work with your doctor to make the switch safely. Never stop taking your HIV medications or change your regimen on your own.
While you explore alternatives, also try Medfinder to see if Darunavir is available at another pharmacy near you. You may not need to switch medications at all. For more on finding your medication, check out how to find Darunavir in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.